Since 2022,

Theracion Biomedical relocated its manufacturing facility to a larger size for a variety of up-coming products and obtained GMP certification.

Acticlot, absorbable haemostat (flowable hemostatic matrix), is approved by the KFDA.

In 2021,

Theracion Biomedical has been studying surgical sealants and adhesives, soft tissue reinforcement products, and topical hemostats. New surgical sealants and soft tissue reinforcement products, will be on the market in the near future. 

In 2020,

Theracion Biomedical entered the Pre-series stage and was funded by Hanmi Healthcare Inc., one of the leading medical device distributors in Korea, with approximately US$ 1.9 million. 

OOZFIX, absorbable haemostat powder, is approved by the KFDA. OOZFIX, a proprietary patent-pending technology, is a plant-based hemostat containing no animal or human components. 

In 2019,

The company acquired the TIPS (Accelerator Investment-Driven Tech Incubator Program for Startup), a government grant for tech start-ups which is designed to identify and nurture the most promising startups with innovative ideas and groundbreaking technologies. It offers seamless services encompassing angel investor networking, incubating, mentoring/professional support, and matching R&D funds. 

Tableau Wax, a newly-developed biodegradable bone hemostasis material, received KFDA approval for distribution in Korea. Certification of CE(MDD) and FDA 510(K) is ongoing. 

Since founded in 2016,

Theracion Biomedical has concentrated on the development of novel topical hemostats. 4 R&D projects for new topical hemostats’ development have been funded with grants from the Ministry of SMEs and Startups, Korea, for approximately US$1.1 million.